1)川上憲人:精神疾患の有病率等に関する大規模疫学調査研究.世界精神保健日本調査セカンド総合研究報告書,2016.http://wmhj2.jp//WMHJ2-2016R.pdf. (2020年3月20日閲覧)
2)Bushnell GA, Stürmer T, Gaynes BN, et al:Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001-2014. JAMA Psychiatry 74:747-755, 2017
3)Sawada N, Uchida H, Suzuki T, et al:Persistence and compliance to antidepressant treatment in patients with depression:a chart review. BMC Psychiatry 9:1-10, 2009
4)American Psychiatric Association:American Psychiatric Association Practice Guideline for the Treatment of Major Depressive Disorder, 3rd ed. American Psychiatric Publishing, Washington D.C., 2010
5)Benasi G, Guidi J, Offidani E, et al:Benzodiazepines as a monotherapy in depressive disorders:a systematic review. Psychother. Psychosom 87:65-74, 2018
6)Laws D, Ashford JJ, Anstee JA:A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatrica Scandinavica 81:185-189, 1990
7)日本うつ病学会気分障害の治療ガイドライン作成委員会:日本うつ病学会治療ガイドラインⅡ.うつ病(DSM-5)/大うつ病性障害2016.https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/20190724.pdf. (2020年3月20日閲覧)
8)National Institute for Health and Clinical Excellence:Depression in adults with a chronic physical problem:recognition and management. Clinical Guideline. 2009. [Online]. https://www.nice.org.uk/guidance/cg91(2020年2月19日閲覧)
9)Ogawa Y, Takeshima N, Hayasaka Y, et al:Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst. Rev 6:2019
10)相原守夫:診療ガイドラインのためのGRADEシステム.中外医学社,2018
11)Cohen J:Statistical power analysis for the behavioral sciences, 2nd ed. Lawrence Erlbaum Associates Publishers, Hillsdale, 1988